TITLE: Tamiflu for Prophylaxis Against Influenza: Clinical and Cost-Effectiveness

DATE: 03 April 2009

RESEARCH QUESTIONS:

1. What is the clinical effectiveness of tamiflu as prophylaxis against influenza?
2. What is the cost-effectiveness of tamiflu as prophylaxis against influenza?

METHODS:

A limited literature search was conducted on key health technology assessment resources, including PubMed, the Cochrane Library (Issue 4, 2008), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI, EuroScan, international HTA agencies, and a focused Internet search. Results include articles published between August 2006 and March 2009 and are limited to English language publications only. Filters were applied to limit the retrieval to health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, controlled clinical trials, observational studies, and economic studies. Internet links are provided, where available.

RESULTS:

HTIS reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, controlled clinical trials, observational studies, and economic evaluations.

Three systematic reviews, one meta-analysis, three observational studies, and one economic evaluation were identified. No health technology assessments, randomized controlled trials or controlled clinical trials were identified. Additional articles of interest are located in the appendix.
Health technology assessments
No literature identified

Systematic reviews and meta-analyses


   Structured abstract available: [http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000001265](http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=10000001265) (accessed 2009 Apr 02).

Randomized controlled trials
No literature identified

Controlled clinical trials
No literature identified

Observational studies


Economic analyses and cost information


PREPARED BY:
Candice McGahern, Research Assistant
Emmanuel Nkansah, MLS, Information Specialist
Health Technology Inquiry Service
Email: [htis@cadth.ca](mailto:htis@cadth.ca)
Tel: 1-866-898-8439
APPENDIX – FURTHER INFORMATION:

Guidelines and recommendations


Review articles


12. Deonandan R, Mensinkai S, Hodgson A. *Effectiveness of neuraminidase inhibitors for prevention of influenza* [Technology Report number 79]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH) 2007. Available: [http://www.cadth.ca/media/pdf/I3004_tr_Neuraminidase_Inhibitors_e.pdf](http://www.cadth.ca/media/pdf/I3004_tr_Neuraminidase_Inhibitors_e.pdf) (accessed 2009 Apr 02).
   Structured abstract available: [http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32007000126


Additional references